Computational Neuroimaging Group (CNG)

Head of the computational neuroimaging group (CNG):

  • Professor Peter Bede

The Computational Neuroimaging Group (CNG) is a large translational research laboratory led by Professor Peter Bede. The CNG is a multidisciplinary lab consisting of neurologists, mathematicians, psychiatrists, psychologists, ophthalmologists, post-doctoral researchers, PhD and MSc students with a shared interest in linking clinical phenomena to structural and functional brain alterations.

The group has been successful in describing phenotype- and genotype-associated imaging signatures and mapping longitudinal trajectories across several time-points from the presymptomatic phase of various disorders to the final stages of neurodegenerative conditions. With a strong emphasis on clinically relevant research questions, the CNG applies a variety of cutting-edge neuroimaging methods to identify, track and characterise disease propagation patterns in vivo. The group’s main interest is Amyotrophic Lateral Sclerosis and Frontotemporal dementia, but they have conducted successful studies in HIV encephalopathy, epilepsy, multiple sclerosis, primary lateral sclerosis, myotonic dystrophy and spinocerebellar ataxia. Professor Bede holds a number of prestigious research grants from a variety national and international funding agencies and the CNG is a contributing member of several international consortia such as ENCALS, TRICALS, NISALS, and Precision ALS.  

The CNG formally publishes its novel research findings in peer-reviewed scientific journals, but also promptly shares their observations with patient charities, advocacy groups, scientific collaborators and industry partners. In addition to pursuing academic research studies, the main mission of the Computational Neuroimaging Group is to develop viable diagnostic and monitoring protocols to aid individualised patient care and improve pharmaceutical trial designs.

For further information, please contact Professor Peter Bede at:

The CNG’s most recent publications are listed at: 

  1. Peter Bede, Parameswaran M. Iyer, Eoin Finegan, Taha Omer, Orla Hardiman. Virtual brain biopsies in amyotrophic lateral sclerosis: diagnostic classification based on in vivo pathological patterns. Neuroimage Clinical 2017 Jun 9;15:653-658. doi: 10.1016/j.nicl.2017.06.010. eCollection 2017. PMID: 28664036
  2. Taha Omer, Eoin Finegan, Siobhan Hutchinson, Mark A. Doherty, Alice Vajda, Russell L. McLaughlin, Niall Pender, Orla Hardiman, Peter Bede. Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study – Amyotroph Lateral Scler Frontotemporal Degener. 2017 May 31:1-13. doi: 10.1080/21678421.2017.1332077. PMID: 28562080 2017
  3. Jennifer Williams, Peter Bede, Colin Doherty. An exploration of the spectrum of peri-ictal MRI change; a comprehensive literature review. Seizure: European Journal of Epilepsy - Seizure. 2017 May 31;50:19-32. doi: 10.1016/j.seizure.2017.05.005.PMID: 28600921  Accepted
  4. Peter Bede, Eoin Finegan, Orla Hardiman. From pneumomyelography to cord tractography: historical perspectives on spinal imaging. Future Neurology. 2017
    Schuster C, Hardiman O, Bede P. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. 2017 Apr 17;17(1):73. doi: 10.1186/s12883-017-0854-x. PMID: 28412941
  5. Tarig Abkur, Peter Bede. Reversible gait ataxia: From wheelchair to independent mobility, Neurology  2017 Apr 11;88(15):e145-e149. doi: 10.1212/WNL.0000000000003815. PMID: 28396457
  6. Peter Bede. From qualitative radiological cues to machine learning: MRI-based diagnosis in neurodegeneration. Future Neurology. February 2017 ,Vol. 12, No. 1, Pages 5-8 , DOI 10.2217/fnl-2016-0029
  7. Christina Schuster, Orla Hardiman, Peter Bede. Development of an automated MRI-based diagnostic protocol for Amyotrophic Lateral Sclerosis using disease-specific pathognomonic features: a quantitative disease-state classification study. PLoS One. 2016 Dec 1;11(12):e0167331. PMID: 27907080
  8. Schuster C, Elamin M, Hardiman O, Bede P. The segmental diffusivity profile of ALS-associated white matter degeneration. Eur J Neurol. 2016 Aug;23(8):1361-71. doi: 10.1111/ene.13038.PMID: 27207250
  9. Bede P, Iyer PM, Schuster C, Elamin M, McLaughlin RL, Kenna K, Hardiman O. "The selective anatomical vulnerability of ALS - “disease-defining” and “disease-defying” brain regions" Amyotroph Lateral Scler Frontotemporal Degener. 2016 Apr 18:1-10. [Epub ahead of print] PMID: 27087114 DOI:10.3109/21678421.2016.1173702
  10. Iyer P, Doherty C, Bede P. Imaging biomarkers in neurodegenerative conditions (Book chapter) Neurodegenerative disorders: A clinical guide – Second Edition, Chapter 2, p 13-27, ISBN: ISBN 978-3-319-23308-6 Springer 2016. DOI 10.1007/978-3-319-23309-3
  11. Editors: Orla Hardiman, Colin P. Doherty, Marwa Elamin, Peter Bede
    Schuster C, Elamin M, Hardiman O, Bede P. Presymptomatic and longitudinal neuroimaging in neurodegeneration: from snapshots to motion picture - a systematic review. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1089-96. doi: 10.1136/jnnp-2014-309888. PMID: 25632156
  12. Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, Fagan A, Bradley DG, Hardiman O. Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):468-70. doi: 10.1136/jnnp-2014-308172. PMID: 25053771
  13. Bede P, Hardiman O. Lessons of ALS imaging: pitfalls, inconsistencies, and future directions – a critical review. Neuroimage Clin. 2014 Feb 27;4:436-443. PMID: 24624329
  14. Bede P, Elamin M, Byrne S, McLaughlin R, Kenna K, Vajda A, Pender N, Bradley DG, Hardiman O. Basal ganglia involvement in Amyotrophic Lateral Sclerosis. Neurology, 2013 Dec 10;81(24):2107-15. PMID: 24212388
  15. Bede P, Bokde ALW, Byrne S, Elamin M, McLaughlin R, Kenna K, Fagan AJ, Pender N, Bradley DG, Hardiman O. A multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology. 2013 Jul 23;81(4):361-9. PMID: 23771489
  16. Bede P, Bokde AL, Elamin M, Bynre S, McLaughlin RL, Jordan N, Hampel H, Gallagher L, Lynch C, Fagan A, Pender N, Hardiman O. Grey matter correlates of clinical variables in Amyotrophic Lateral Sclerosis– a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):766-73. PMID: 23085933
  17. Bede P, Bokde AL, Byrne S, Elamin M, Fagan AJ, Hardiman O. Spinal cord markers in ALS: Diagnostic and biomarker considerations. Amyotroph Lateral Scler. 2012 Sep;13(5):407-15. PMID: 22329869
  18. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O'Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012 Mar;11(3):232-40. PMID: 22305801